{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_codes_comments in Code Comments (approximate match)
Status:
US Previously Marketed
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Stramonium U.S.P.
(1921)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Oil of Eucalyptus U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Oil of Eucalyptus U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative senna pod concentrate
Source URL:
First approved in 2019
Source:
LAXATIVES RUBILAX by Lydia Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2013
Source:
PAMO Kill Natural by GeoRim Pharmaceutical
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Migraine Relief by Rida LLC
(2023)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125254
(2007)
Source URL:
First approved in 2007
Source:
BLA125254
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2001
Source:
Preferred Plus Urinary Pain Relief by Kinray
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03855176: Phase 4 Interventional Completed Hepatitis A
(2017)
Source URL:
First approved in 1996
Source:
BLA103606
Source URL:
Class:
STRUCTURALLY DIVERSE